To the Editor The decision to initiate oral anticoagulation (OAC) posthemorrhagic stroke or traumatic intracerebral hemorrhage (ICH) in those with atrial fibrillation (AF) is a gray area in clinical practice. By showing that the decision to resume OAC may have a favorable risk-benefit ratio, the article by Nielsen et al¹ published in a recent issue of JAMA Internal Medicine brings us closer to understanding if and when to do this. However, important questions remain, which may be difficult to clarify using such an observational approach.

中文翻译：

---

并非所有类型的出血性中风均会产生

给编辑的决定对于患有房颤（AF）的患者，决定开始出血性中风后口服抗凝（OAC）或外伤性脑出血（ICH）是临床实践中的一个灰色区域。通过表明恢复OAC的决定可能具有有利的风险收益率，Nielsen等人¹在最近一期JAMA Internal Medicine上发表的文章使我们更加了解是否以及何时进行此操作。但是，仍然存在重要的问题，使用这种观察方法可能难以澄清。